Late complications and survival of soft tissue sarcoma patients after adjuvant chemotherapy – a single tertiary centre experience

Figures & data

Table 1. Patient characteristics of the two treatment groups.

Characteristics	Chemotherapy group, n = 33 (%)	Chemo- and radiation therapy group, n = 34 (%)
Gender
Male	16 (48.5)	19 (55.9)
Female	17 (51.5)	15 (44.1)
Age
<65 years	20 (60.6)	23 (67.6)
≥65 years	13 (39.4)	11 (32.4)
Treatment phase
Primary tumour	25 (75.8)	33 (97.1)
Local recurrence	4 (12.1)	1 (2.9)
Metastasis operation	4 (12.1)	0
Primary site
Extremities	12 (36.4)	22 (64.7)
Retroperitoneum	16 (48.5)	6 (17.6)
Trunk	4 (12.1)	3 (8.8)
Head and neck	1 (3.0)	3 (8.8)
Histological subtypes
Liposarcoma	8 (24.2)	8 (23.5)
Leiomyosarcoma	8 (24.4)	4 (11.8)
Fibrosarcoma	5 (15.2)	7 (20.6)
UPS	4 (12.1)	7 (20.6)
Synovial sarcoma	2 (6.1)	3 (8.8)
MPNST	2 (6.1)	2 (5.9)
Others	4 (12.1)	3 (8.8)
Grade
1	1 (3.0)	1 (2.9)
2	6 (18.2)	6 (17.6)
3	26 (78.8)	27 (79.4)

Abbreviations: UPS = undifferentiated pleomorphic sarcoma; MPNST = malignant peripheral nerve sheath tumour

Figure 1. Cumulative dose of doxorubicin for patients. Patients who developed heart failure are highlighted with red colour.

Figure 2. Overall survival of the patients in this study. Vertical lines represent patients who were alive at the end of the follow-up.

Data availability statement

At present, the Finnish legislation on secondary uses of healthcare data and patient records does not permit sharing this type of data. Therefore, the datasets generated and used for this study cannot be made available. Documentation on data collection process and dataset are available from the corresponding author on reasonable request.